Paul Tudor Jones Fibrogen Inc Transaction History

Tudor Investment Corp Et Al

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.79 - $2.83 $391 - $1,400	-495 Reduced 1.02%	48,199 $41,000
Q2 2023 Aug 14, 2023	SELL	$2.49 - $20.59 $3,279 - $27,117	-1,317 Reduced 2.63%	48,694 $131,000
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $797,675 - $1.26 Million	50,011 New	50,011 $933,000
Q2 2022 Aug 15, 2022	SELL	$7.94 - $12.96 $51,387 - $83,877	-6,472 Reduced 4.9%	125,523 $1.33 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $1.59 Million - $2.22 Million	131,995 New	131,995 $1.59 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $626,483 - $970,955	-63,090 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $359,883 - $941,777	35,352 Added 127.45%	63,090 $645,000
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $515,094 - $989,691	27,738 New	27,738 $739,000
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $433,433 - $487,305	-10,710 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $348,824 - $458,709	10,710 New	10,710 $434,000
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $251,292 - $349,252	-7,267 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $268,733 - $352,086	7,267 New	7,267 $269,000
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $555,991 - $755,829	-12,260 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $201,779 - $289,081	-4,810 Reduced 28.18%	12,260 $581,000
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $570,138 - $920,073	17,070	17,070 $918,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.